Unyango lweSeli ye-NK oludityaniswe ne-DC Vaccine lubonisa ukuphucuka okukhulu kumhlaza wesibindi okwinqanaba lokugqibela
Inkqubela phambili kwezonyango yakutshanje Unyango lwe-immunotherapy Inika ithemba elitsha kwizigulana ezinomhlaza wesibindi okwinqanaba lokugqibela, ingakumbi ezo zinokhetho oluncinci lonyango. Kwityala elimangalisayo elivela eJapan, isigulana esine-advanced hepatocellular carcinoma (HCC) sifumene unyango olutsha oludibeneyo olubandakanya iiseli zokubulala zendalo (NK), ii-dendritic cell vaccines (DC), kunye neNivolumab, nto leyo ebangele ukuphucuka okumangalisayo kwiiveki ezintandathu kuphela.
Isigulana, esafunyaniswa sine-HCC ekwinqanaba lokugqibela kunye ne-metastases ebanzi kwi-lymph nodes, imiphunga, kunye namathambo, sasingenaso isiqinisekiso esifanelekileyo ngonyango lwendabuko. Ngenxa yokungasebenzi kakuhle kwesibindi, inani eliphantsi le-lymphocyte, kunye nokugcinwa kwesibindi okuncinci, iqela lakhe lezonyango lalingenazo iindlela ezininzi. Baqalise inkqubo epheleleyo ye-immunotherapy, edibanisa ii-DC vaccines kunye ne-Nivolumab kunye ne- Iseli yaseNk unyango olunikwa rhoqo emva kweeveki ezintathu kwimijikelo emithathu.
Okumangalisayo kukuba, emva kweeveki ezintandathu kuphela zonyango, ukusebenza kwesibindi sesigulana kwaphucuka kakhulu, ukusuka kudidi lwe-Child-Pugh lwe-C (olusezantsi kangangoko) ukuya kwi-A (imeko enempilo kakhulu). Olu tshintsho luhambisane nokuncipha okukhulu kobukhulu bethumba, ukunyamalala kwe-ascites, kunye nokwehla kweempawu zethumba.
Iiseli ze-NK, okanye iiseli zokubulala zendalo, luhlobo lweseli yomzimba ekwaziyo ukubona nokutshabalalisa iiseli ezingaqhelekanga, ezifana neeseli zomhlaza, ngaphandle kwesidingo soqeqesho lwangaphambili. Oku kuzenza ziphumelele kakhulu ekujoliseni nasekupheliseni iiseli zethumba ngokukhawuleza. Nangona kunjalo, kwizigulane ezinezifo ezingapheliyo okanye umhlaza ophucukileyo, ukusebenza kakuhle kweeseli ze-NK kunokuphazamiseka. Ukujongana noku, abaphandi baye baphuhlisa iindlela zokuphucula umsebenzi weeseli ze-NK ngokusebenzisa ubunjineli bemfuza kunye nonyango oludibeneyo.
Kule meko, unyango lwe-NK cell lwaludibene ne-DC vaccine, eyenzelwe ukuvuselela inkqubo yomzimba yesigulana, kunye ne-Nivolumab, i-checkpoint inhibitor ethintela amandla omhlaza okuphepha iimpendulo zomzimba. Kumjikelo wesithandathu wonyango, ii-CT scans zabonisa ukwehla okukhulu kobukhulu be-tumor, kwaye imeko iyonke yesigulana yaphucuka ngokwaneleyo ukuba itshintshele kwi-chemotherapy regimen eqhelekileyo. Iziphumo zelebhu zikwabonise ukwehla okuphawulekayo kwi-tumor markers, kubandakanya i-vitamin K deficiency-induced protein-Ⅱ (PIVKA-II), kunye nokubuyiselwa kwenani leeseli zegazi ezimhlophe zesigulana kunye namanqanaba e-lymphocyte.
Eli tyala libonisa indlela unyango lwe-immunotherapy, ingakumbi unyango olusekelwe kwiiseli ze-NK, olunokuba luncedo ngayo kwizigulana ezinomhlaza ophucukileyo ezineendlela zonyango ezilinganiselweyo. Ukudibana ngempumelelo kweeseli ze-NK kunye nezinye iindlela zonyango ezifana ne-DC vaccines kunye ne-checkpoint inhibitors kuvula amathuba amatsha okunyanga umhlaza, ngakumbi kwabo babonwa bengasebenzi okanye abanonyamezelo oluphantsi lonyango.
Amandla onyango lwe-NK cell okuguqula iindlela zonyango lomhlaza awanakulinganiswa. Ayiboneleli nje kuphela ngoncedo lwezigulane ezineendlela ezimbalwa ezisele, kodwa ikwavula indlela yokuqhubela phambili kwixesha elizayo kunyango lomntu ngamnye kunye nonyango olusekelwe kumzimba. Nangona eli tyala linika umbono wethemba, likwagxininisa isidingo sophando oluqhubekayo ukuqinisekisa ukuba olu nyango lubalaseleyo luyafikeleleka kwaye lulungelelaniswe ngakumbi kubantu abaninzi abagulayo.
Njengoko icandelo le-immunotherapy liqhubeka nokukhula, eli tyala lisebenza njengobungqina bamandla amakhulu akhoyo kunyango olusekelwe kumzimba olawulayo okuguqula ikamva lokhathalelo lomhlaza.